Phase 4 N=270 Trichomonas Vaginalis Recurrence Among HIV+ Women
Trichomonas Infections · HIV Infections
Primary: TV Culture Positive Result — 11; 21 participants — p=.045
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=40 Neo-Penotran Forte Vaginal Suppository for Vaginal Trichomoniasis
Trichomonas Vaginitis
Primary: Percentage of Participants Cured of Vaginal Trichmonas — 90; 90; 88 percentage of participants
Phase 3 N=623 Trichomonas Vaginalis Repeat Infections Among HIV Negative Women
Vaginitis Trichomonal or Due to Trichomonas
Primary: Number of Subjects That Were Trichomonas Vaginalis (TV) Positive After Treatment With Metronidazole (MTZ) — 58; 34 Participants
N/A N=519 A Validation Study of Genzyme Diagnostics OSOM Trichomonas Rapid Test and BVBlue Test
Bacterial Vaginosis · Urogenital Infection by Trichomonas Vaginalis
Primary: Sensitivity of the OSOM Rapid Test and PCR Wet Mount Microscopy in Diagnosing Trichomonas Vaginalis in Symptomatic and Asymptomatic Women — 92; 91; 100; 100 Percentage…
Phase 2 N=234 Topical Metronidazole and Miconazole Co-formulated Vaginal Suppositories for Preventing Vaginal Infections in HIV-seronegative Women
Bacterial Vaginosis · Candidiasis · Trichomoniasis
Primary: Efficacy of Monthly Periodic Presumptive Treatment (PPT) Using Metronidazole With Miconazole Intravaginal Suppositories Versus Matching Placebo Nightly for Five Nights…
Phase 4 N=593 Treatment of Bacterial Vaginosis (BV) With Tinidazole
Bacterial Vaginosis
Primary: Cure of Bacterial Vaginosis — 75; 73; 77 participants
Phase 3 N=184 Trial of Trimosan Gel Effect on Pessary-associated Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Patients With Bacterial Vaginosis at 3 Months — 15; 16 Participants
Phase 3 N=1,365 Bacterial Vaginosis Home Screening to Prevent STDs
Bacterial Vaginosis
Primary: One-year Incidence of Chlamydial and Gonococcal Infections in Women Who Receive Screening (Every 2 Months) and Treatment for Asymptomatic Bacterial Vaginosis as Compared…
Phase 3 N=475 Multi-Center Study of New Medications to Treat Vaginal Infections
Vaginal Infection
Primary: Clinical Cure of Mixed Infection (BV and VVC) as Assessed by the Investigator at the Test-of-cure Visit — 31; 29; 43 Participants — p=0.030
Phase 3 N=160 A Study to Compare Efficacy and Safety of an Ovule Containing Terconazole, Clindamycin and Fluocinolone Versus an Ovule Containing Metronidazole, Nystatin and Fluocinolone in the Treatment of Secondary Vulvar/ or Vaginal Symptoms of Infectious Vaginitis/ and Infectious Vaginosis
Vaginitis · Infectious Vaginosis
Primary: Percentage of Participants With Presence or Absence of Symptoms 3 Days After Treatment — 67.1; 79.2; 32.9; 20.8 Percentage of Participants
Phase 3 N=204 Multi-Center Study of New Medications to Treat Vaginal Infections
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 18 Participants — p=<0.001
Phase 3 N=212 Multi-Center Study of New Medications to Treat Vaginal Infections
Vaginal Infection
Primary: Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit — 47; 25 Participants — p=0.002
Phase 4 N=12 Asymptomatic Bacterial Vaginosis and Herpes Simplex Virus Type 2 (BV/HSV-2) Shedding Study
Bacterial Vaginosis
Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants
N/A N=35 Study of How Bacterial Vaginosis and Its Treatment Affects Cervical and Vaginal Tissue
Bacterial Vaginosis · Vaginal Discharge
Primary: p24 Antigen Production in Tissue
N/A N=351 Point of Care Diagnosis of Vaginal Infections
Vaginitis · Bacterial Vaginosis · Yeast Vaginitis
Primary: Number of Participants Prescribed Appropriate Treatment — 61; 104; 58; 21 Participants — p=<.001
N/A N=705 Women's Improvement of Sexual Health (WISH) Demonstration Project
Sexually Transmitted Disease · Bacterial Vaginosis · Vaginal Candidiasis
Primary: Feasibility of Integrating Point-of-care Testing (Monitoring & Evaluation Indicators) — 396; 378; 399; 216 Participants
N/A N=54 Recurrent Bacterial Vaginosis and Vaginal Acidifying Gel Trial
Bacterial Vaginosis
Primary: Recurrent Bacterial Vaginosis — 7; 7 Participants — p=0.75
Phase 3 N=251 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 68; 25 Participants — p=<0.001
Phase 3 N=250 A Phase 3 Study of SPL7013 Gel (VivaGel) for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Women With Clinical Cure at the End of Treatment Visit (EOT) — 59; 19 Participants — p=<0.001
N/A N=50 Clinical Investigation To Evaluate Cerviron Ovules® in Symptomatic Vaginitis
Vaginitis and Vulvovaginitis
Primary: Number of Participants With the Same Gynaecological Conditions at the End of Treatment Visit — 13 Participants
Phase 3 N=658 Assessment of the Efficacy of POLYGYNAX® in the Empirical Treatment of Infectious Vaginitis
Vaginitis
Primary: Clinical Treatment Efficacy Assessed by the Investigator After Thorough Gynaecological Examination and Patient's Interview at End of Treatment Visit — 275; 268; 27; 41…
Phase 2 N=109 Safety and Efficacy of 5% Monolaurin Vaginal Gel Administered Intravaginally for the Treatment of Bacterial Vaginosis
Bacterial Vaginosis
Primary: Number of Participants With Clinical Cure in Each Study Arm — 11; 8 Participants — p=0.420
N/A N=1,585 Clinical Study of a Diagnostic Device for NG, TV and CT in Women
Chlamydial Infection · Gonococcal Infection · Trichomoniasis
Primary: The i) Percent Sensitivity and ii) Percent Specificity of Click Device for Detection of Chlamydia Trachomatis (CT) in Self-collected Vaginal Specimens as Compared to PIS…
Phase 2 N=228 LACTIN-V Study for Recurrent Bacterial Vaginosis
Bacterial Vaginosis
Primary: The Proportion of Participants Reporting Product-related Adverse Events (AEs) and Serious Adverse Events (SAEs) in Each Study Arm. — 0.11; 0.07 proportion of…
Phase 2 N=81 Suppression Of Bacterial Vaginosis (BV) [SUBVert]
Bacterial Vaginosis
Primary: Proportion of Participants With Recurrent Bacterial Vaginosis (RBV) by Visit 4, as Defined by Presence of at Least 3 Amsel Criteria — 0.581; 0.697 proportion of…
Phase 4 N=140 Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Vulvovaginal Candidiasis
Primary: Mycological Cure 1 — 46; 47 Participants
Phase 3 N=147 A Phase 3 Study of Solosec® for the Treatment of Trichomoniasis
Trichomonas Infection
Primary: Microbiological Cure at the TOC Visit — 59; 1 Participants
N/A N=68 Rwanda Vaginal Microbiota Restoration Study
Bacterial Vaginosis
Primary: Bacterial Vaginosis (BV) Incidence by Modified Amsel Criteria — 7.53; 2.04; 3.36; 3.35 Incidence: events per PY at risk
Phase 3 N=189 A Phase 3 Study of SYM-1219 Treatment of Women and Post-Menarchal Adolescent Girls With Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Outcome Responder Rate — 57; 11; 50; 46 Participants
N/A N=24 Clinical Performance of a Vaginal Pessary (pHyph) in Bacterial Vaginosis
Bacterial Vaginosis
Primary: Clinical Cure Rate — 18 Participants